Results 21 to 30 of about 5,546 (214)

Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly

Endocrine Connections, 2023
Pasireotide long-acting release is effective in achieving bioche mical control and reducing tumour volume in patients with acromegaly inadequately controll ed by first-line therapy.
Nelma Veronica Marques, Luiz Eduardo Armondi Wildemberg, Monica R Gadelha   +2 more
doaj   +1 more source

Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR

Endocrine Connections, 2022
Objective: Pasireotide is a second-generation somatostatin receptor ligand (SRL) used for treating acromegaly. Its clinical use is limited by adverse effe cts on glucose homeostasis. The aim of this study was to evaluate longitudinal changes in beta-cell
Peter Wolf, Alexandre Dormoy, Luigi Maione, Sylvie Salenave, Jacques Young, Peter Kamenický, Philippe Chanson   +6 more
doaj   +1 more source

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease

Frontiers in Endocrinology, 2023
ObjectiveThis study evaluated short- and long-term efficacy and safety of the second-generation somatostatin receptor ligand pasireotide alone or in combination with dopamine agonist cabergoline in patients with Cushing’s disease (CD).Study designThis is
Richard A. Feelders, Maria Fleseriu, Pinar Kadioglu, Marie Bex, Deyanira González-Devia, Cesar Luiz Boguszewski, Dilek Gogas Yavuz, Heather Patino, Alberto M. Pedroncelli, Alberto M. Pedroncelli, Ricardo Maamari, Arghya Chattopadhyay, Beverly M. K. Biller, Rosario Pivonello   +13 more
doaj   +1 more source

A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.

PLoS ONE, 2021
BackgroundAllogeneic hematopoietic stem cell transplantation (HCT) is an often curative intent treatment, however it is associated with significant gastrointestinal (GI) toxicity and treatment related mortality. Graft-versus-host disease is a significant
Sendhilnathan Ramalingam, Sharareh Siamakpour-Reihani, Lauren Bohannan, Yi Ren, Alexander Sibley, Jeff Sheng, Li Ma, Andrew B Nixon, Jing Lyu, Daniel C Parker, James Bain, Michael Muehlbauer, Olga Ilkayeva, Virginia Byers Kraus, Janet L Huebner, Thomas Spitzer, Jami Brown, Jonathan U Peled, Marcel van den Brink, Antonio Gomes, Taewoong Choi, Cristina Gasparetto, Mitchell Horwitz, Gwynn Long, Richard Lopez, David Rizzieri, Stefanie Sarantopoulos, Nelson Chao, Anthony D Sung   +28 more
doaj   +1 more source

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly

Endocrine Connections, 2020
Pasireotide, a multireceptor-targeted somatostatin analog with highest affinity for somatostatin receptor subtype (SST) 5, has demonstrated superio r efficacy over the SST2-preferential somatostatin analogs octreotide and lanreotide.
Mônica R Gadelha, Feng Gu, Marcello D Bronstein, Thierry C Brue, Maria Fleseriu, Ilan Shimon, Aart J van der Lely, Shoba Ravichandran, Albert Kandra, Alberto M Pedroncelli, Annamaria A L Colao   +10 more
doaj   +1 more source

Role of somatostatin receptors in normal and tumoral pituitary corticotropic cells [PDF]

, 2010
Normal and tumoral pituitary corticotropic cells express sst2and sst5, of which sst5is the predominantly expressed receptor subtype. Somatostatin (SS) inhibits pituitary adrenocorticotropin hormone (ACTH) secretion in vitro, but the sensitivity to SS is ...
Feelders, R.A. (Richard), Hofland, L.J. (Leo), Lamberts, S.W.J. (Steven)   +2 more
core   +13 more sources

Evaluation of PepT1 (SLC15A1) Substrate Characteristics of Therapeutic Cyclic Peptides

Pharmaceutics, 2022
The human peptide transporter hPepT1 (SLC15A1), physiologically transporting dipeptides and tripeptides generated during food digestion, also plays a role in the uptake of small bioactive peptides and peptide-like drugs.
Gzona Bajraktari-Sylejmani, Teresa von Linde, Jürgen Burhenne, Walter Emil Haefeli, Max Sauter, Johanna Weiss   +5 more
doaj   +1 more source

Medical Management of Polycystic Liver Disease: A Position Statement From the European Reference Network on Hepatological Diseases. [PDF]

Liver Int
ABSTRACT Polycystic liver disease (PLD) is a rare genetic disorder characterised by progressive liver enlargement due to multiple cysts. The main symptoms are liver volume‐related. Although randomised controlled trials have shown that somatostatin analogues (SSAs) reduce liver volume as well as symptoms, specific guidance on when and how to use SSAs in
Heinrich S, de Matos AMC, Colmenero J, Elsharkawy AM, Fraňková S, Halbritter J, Mrzljak A, Müller RU, Pereira R, Strnad P, Teemer CAJ, Verbeek J, Wronka KM, Nevens F, Taubert R, Drenth JPH, European Reference Network on Hepatological Liver Diseases (ERN RARE‐LIVER).   +16 more
europepmc   +2 more sources

Cushing’s disease: Does low-dose pasireotide offer a comparable efficacy and safety to high-dose?

Endocrinology, Diabetes & Metabolism Case Reports, 2021
Whilst literature is expanding on pasireotide use in the management of Cushing’s disease (CD), there is still currently much unknown about long-term and low-dose pasireotide use in CD. We present a 60-year-old female with residual CD after transphenoidal
Mimi Wong, Usman H Malabu, Ipeson Korah, YongMong Tan   +3 more
doaj   +1 more source

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future [PDF]

, 2019
In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased. Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases are diagnosed at advanced stages, when curative treatment options are no ...
Amthauer, Holger, Jann, Henning, Kayser, Antonin, Roderburg, Christoph, Stueven, Anna Kathrin, Tacke, Frank, Wetz, Christoph, Wiedenmann, Bertram, Wree, Alexander   +8 more
core   +1 more source